SiSaf Ltd
Dr. Suzanne Saffie-Siebert has a diverse work experience in various roles and companies. Dr Suzanne is currently serving as the Chairwoman & CEO of SiSaf Ltd, a RNA delivery and therapeutics company that specializes in developing RNA therapeutics for rare genetic disorders. Prior to this role, they were the CEO of SiSaf Ltd for eight years.
Dr Suzanne also holds the position of Chairwoman & Chief Good Scientist at Good Science Beauty, a skincare company that uses Good Silicon+ technology for effective skincare solutions.
Dr. Saffie-Siebert has also served as a Visiting Professor at Ulster University since 2010. Additionally, they were the Chairwoman of Autism Biotech Ltd from 2013 to 2020.
Before these roles, they worked as the Director of Research at pSiMedica Ltd and as the Head of Drug Delivery Centre at Dompé.
Dr. Suzanne Saffie-Siebert completed their Doctor of Philosophy (PhD) degree in Drug Delivery at The School of Pharmacy, University of London from 1994 to 1998. In 2006, they pursued a BioScience Business Diploma at Oxford Brookes University, specializing in Business/Office Automation/Technology/Data Entry. No end year is provided for their diploma program.
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.